Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CADL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Aglatimagene Besadenovec (CAN-2409) | Non-squamous, Non-Small Cell Lung Cancer | Phase 3 · NCT07660094 | Recruiting |
| Oncolytic HSV-1 rQNestin34.5v.2 | Malignant Glioma of Brain | Phase 1 · NCT03152318 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not CADL's own candidates): Docetaxel Anhydrous, Pembrolizumab, Valacyclovir, Temozolomide, Cyclophosphamide, Nivolumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CADL holds $201.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $17.6M/quarter from operations, an estimated runway of 34.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 34 · Moderate
We believe our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2028.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CADL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR, LLC | Institution (13F) | 10,990,535 | 14.36% | 2026-06-30 |
| RTW Investments, LP | Institution (13G, 5%+) | 6,422,018 | 8.39% | 2026-03-31 |
| Paul B Manning Director · +53,057 options |
Insider | 5,748,279 | 7.51% | 2026-02-23 |
| BlackRock, Inc. | Institution (13G, 5%+) | 4,834,899 | 6.32% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 3,549,823 | 4.64% | 2026-06-30 |
| Acorn Capital Advisors, LLC | Institution (13F) | 3,497,948 | 4.57% | 2026-06-30 |
| Portolan Capital Management, LLC | Institution (13F) | 3,490,398 | 4.56% | 2026-06-30 |
| Saturn V Capital Management LP | Institution (13F) | 3,303,686 | 4.32% | 2026-06-30 |
| Vanguard Capital Management LLC | Institution (13F) | 2,694,040 | 3.52% | 2026-06-30 |
| Geode Capital Management, LLC | Institution (13F) | 1,571,021 | 2.05% | 2026-06-30 |
| Millennium Management Llc | Institution (13F) | 1,093,905 | 1.43% | 2026-06-30 |
| Christopher Martell Director · +46,240 options |
Insider | 546,863 | 0.71% | 2025-06-25 |
Share count 76,518,565 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-11 filed 2026-09-11 |
Tak Paul Peter |
Sale (S) | 59,379 | $10.46 | 113,321 |
| 2026-09-10 filed 2026-09-11 |
Tak Paul Peter |
Option exercise (M) | 125,000 | – | – |
| 2026-09-10 filed 2026-09-11 |
Tak Paul Peter |
Sale (S) | 220,866 | $11.50 | 172,700 |
| 2026-09-10 filed 2026-09-11 |
Tak Paul Peter |
Option exercise (M) | 125,000 | $1.55 | 393,566 |
| 2026-09-08 filed 2026-09-10 |
Zimmermann Martine |
Option award (A) | 64,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CADL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →